Extended Half-life Recombinant Factor VIII (Rurioctocog Alfa Pegol) [Adynovate]

[SDL] Extended half-life recombinant factor VIII (Rurioctocog alfa pegol) [Adynovate] Injection, 250 international units, 500 international units, 1,000 international units, 1,500 international units, 2,000 international units, 3,000 international units

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

19/12/2022 Recombinant blood products for prophylaxis and management of haemophilia A and B>

[R] The Ministry of Health’s Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:

• Octocog alfa (Advate) 250 international units, 500 international units, 1000 international units and 1500 international units powder and solvent for solution for injection

• Rurioctocog alfa pegol (Adynovate) 250 international units, 500 international units, 1000 international units, 1500 international units, 2000 international units and 3000 international units powder and solvent for solution for injection

• Nonacog alfa (BeneFIX) 250 international units, 500 international units, 1000 international units and 2000 international units powder and solvent for solution for injection

[NR] Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.

The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.